SCHEMBL7560635

SCHEMBL7560635

COc1ccc2cc(C(=O)c3ccccc3C(=O)O)ccc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.66
CDC25B P30305 3/20 0.59
HSD17B10 Q99714 2/20 0.58
CDC25A P30304 1/20 0.58
ALDH1A1 P00352 6/20 0.56
HPGD P15428 3/20 0.54
LMNA P02545 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 2/20 0.54
HTT P42858 2/20 0.54
PGR P06401 1/20 0.54
CYP2D6 P10635 1/20 0.54
SLC6A2 P23975 1/20 0.54
PDE4A P27815 1/20 0.54
MAPK1 P28482 1/20 0.54
HRH1 P35367 1/20 0.54
SLC6A3 Q01959 1/20 0.54
PDE4D Q08499 1/20 0.54
AKR1C3 P42330 2/20 0.53
POLB P06746 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560673 0.87 KDM4E (0.60) KDM4ECDC25BHSD17B10CDC25AALDH1A1
SCHEMBL7558808 0.87 KDM4E (0.55) KDM4EHSD17B10ALDH1A1HPGDLMNA
SCHEMBL7449750 0.86 KDM4E (0.68) KDM4EHSD17B10ALDH1A1HPGDLMNA
SCHEMBL238088 0.85 KMT2A (0.68) KDM4ECDC25BHSD17B10CDC25AALDH1A1
SCHEMBL1375270 0.85 KMT2A (0.68) KDM4ECDC25BHSD17B10CDC25AALDH1A1
SCHEMBL9196432 0.84 POLB (0.64) CDC25BHSD17B10CDC25AALDH1A1HPGD
SCHEMBL7708564 0.84 KDM4E (0.69) KDM4EHSD17B10ALDH1A1HPGDLMNA
SCHEMBL7828608 0.84 CDC25B (0.70) KDM4ECDC25BHSD17B10CDC25AALDH1A1
SCHEMBL7459910 0.83 KDM4E (0.59) KDM4EHSD17B10ALDH1A1HPGDCYP1A2
P-Anisic Acid SCHEMBL3660840 0.83 CA1 (0.67) KDM4ECDC25BHSD17B10CDC25AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052354-A1 Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction SCHERING AG 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052354-A1 Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction TNNI3, NPR1, LPXN KDM4E 2293/4885CDC25B 4031/4885HSD17B10 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.